Should I Buy DCBO? DCBO 2026 Analysis

Should You Buy Docebo Inc (DCBO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

19.080

1 Day change

0.32%

52 Week Range

43.400

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now for a catalyst-driven setup: shares at $19.20 are below the company’s announced buyback price ($20.40), creating a near-term upside magnet (~6%).
Trend is still technically bearish, but momentum is starting to improve (MACD turning up) and the buyback provides a practical floor for an impatient entry.
Plan-style takeaway (no waiting): buy now with the expectation of a move toward $20.00–$20.40; reassess if price loses $18.31 support or if it cleanly rejects at $19.99–$20.51 resistance.

Technical Analysis

Trend: Bearish structure (SMA_200 > SMA_20 > SMA_5) suggests the broader trend remains down.
Momentum: MACD histogram +0.0898 and expanding → bullish momentum is improving.
RSI: RSI_6 48.97 (neutral) → not overbought; room for upside if buyers step in.
Key levels:
- Pivot: 19.15 (price is sitting right on it, indicating an inflection point)
- Support: 18.31 (S1) then 17.79 (S2)
- Resistance: 19.99 (R1) then 20.51 (R2)
Pattern-based forward odds (given): +0.8% next day, but -2.22% next week and -5.97% next month → supports a shorter-horizon buy rather than a long hold.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning (Open Interest): Put/Call OI 0.19 → call-heavy positioning (generally bullish sentiment/hedging skew).
Today’s flow (Volume): Put/Call volume 2.0 (puts > calls) but on very small total volume (3 contracts) → bearish read is low confidence.
Volatility: IV (30d) ~70 vs historical vol ~32; IV percentile ~67 → options are pricing elevated moves (often around catalysts like buybacks/earnings).
Activity vs normal: Today’s option volume is ~21.43x the 30-day average (from a low base), suggesting a sudden spike in attention.

Technical Summary

Sell

Buy

Positive Catalysts

- Share buyback catalyst: Company announced a $60M buyback to repurchase ~10.23% of shares at $20.40, funded by cash + credit drawdown → provides an immediate price anchor above current levels.
- Hedge fund behavior: “Hedge Funds are Buying” with buying amount up 1100% QoQ → supportive institutional demand signal.
- Upcoming earnings: QDEC 2025 earnings on 2026-02-27 (pre-market) can act as a volatility/catalyst window (market expects EPS est. 0.31).

Neutral/Negative Catalysts

- Technical overhang: Moving averages remain stacked bearishly (SMA_200 > SMA_20 > SMA_5), meaning rallies can still face selling pressure.
- Short-term statistical drift (given): Similar-pattern outlook points to weakness over the next week/month.
- Financing optics: Buyback partly funded by a credit facility drawdown, which can imply leverage trade-offs and near-term margin digestion (also echoed by analyst commentary).
- No notable insider accumulation: Insider trend listed as neutral (no strong confidence boost from insider buying).

Financial Performance

Latest reported quarter: 2025/Q3
- Revenue: $61.62M, +11.16% YoY (steady growth)
- Net Income: $6.11M, +23.19% YoY (profit growth faster than revenue)
- EPS: $0.21, +31.25% YoY (strong per-share improvement)
- Gross Margin: 79.16%, -0.48% YoY (slight compression, still very high margin profile)
Overall: fundamentals show healthy growth + improving profitability, with a minor gross margin dip.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend: Mostly constructive, with some target trims.
- Scotiabank (2026-01-30): PT cut $35 → $32, reiterates Outperform; cites strong core ARR and attractive valuation despite margin digestion.
- Cantor Fitzgerald (2025-12-24): Initiated Overweight, PT $35.
- ATB Capital (2025-12-10): Upgraded to Outperform, PT C$50.
- Morgan Stanley (2025-11-10): PT cut $34 → $28, keeps Equal Weight.
Wall Street pros: recurring theme of underlying ARR strength, valuation appeal, and supportive capital return (buyback).
Wall Street cons: margin digestion and a more tempered stance from at least one major bank (Equal Weight, lower PT).
Politicians / influential figures: No data provided indicating notable recent buying/selling by politicians or other influential figures.
Congress trading (90 days): No recent congress trading data available.

10 Analyst Rating

Wall Street analysts forecast DCBO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCBO is 35.33 USD with a low forecast of 28 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 19.020

Low

Averages

35.33

High

Current: 19.020

Low

Averages

35.33

High

Scotiabank

Outperform

NULL

downgrade

$35 -> $32

AI Analysis

2026-01-30

Reason

Scotiabank

Price Target

$35 -> $32

AI Analysis

2026-01-30

downgrade

Outperform

NULL

Reason

Scotiabank lowered the firm's price target on Docebo to $32 from $35 and keeps an Outperform rating on the shares. The company's preliminary Q4 results indicate an "impressive" core ARR performance, the analyst tells investors. While the firm anticipates a period of margin digestion, Scotiabank sees the signs of underlying strength and the stock's attractive valuation as a compelling entry point.

Cantor Fitzgerald

initiated

$35

2025-12-24

Reason

Cantor Fitzgerald

Price Target

$35

2025-12-24

initiated

Reason

Cantor Fitzgerald assumed coverage of Docebo with an Overweight rating and $35 price target. The firm is updating research coverage in the Security & Infrastructure Software sector due to analyst departure and reallocation of analyst resources.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DCBO

Unlock Now

DCBO Should I Buy

DCBO Should I Buy

Should You Buy Docebo Inc (DCBO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch